|Inogen -- USA Stock|| |
USD 141.23 0.79 0.56%
Independent Chairman of the Board
Dr. Heath Lukatch, Ph.D., is an Independent Chairman of the Board of Inogen, Inc. Dr. Lukatch has served as Chairperson of our Board since 2008, and as a director since 2006. Dr. Lukatch is employed as a Partner and Managing Director at TPG Biotech. Dr. Lukatch joined TPG Biotech in 2015. Prior to joining TPG Biotech, Dr. Lukatch was a Partner at Novo Ventures Inc., which provides certain consultancy services to Novo AS. Dr. Lukatch joined Novo Ventures Inc. in 2006. From 2001 to 2006, Dr. Lukatch was a Managing Director responsible for biotechnology venture investments at Piper Jaffray Ventures and SightLine Partners, a private equity firm and spin off of Piper Jaffray Ventures. Prior to joining Piper Jaffray Ventures, Dr. Lukatch worked as a strategy consultant with McKinsey Company, a consulting firm, from 1997 to 2000. Dr. Lukatch also served as cofounder and Chief Executive Officer of AutoMate Scientific, a biotechnology instrumentation company from 1991 to 1997, and held scientific positions with Chiron Corporationrationration, a biotechnology company, from 1990 to 1991, Roche Bioscience, a healthcare company, from 1996 to 1997, and Cetus Corporationrationration, a biotechnology company, in 1987. He currently serves on the Boards of Directors of Adynxx Flexion Therapeutics, Inc. and Satsuma Pharma. Dr. Lukatch previously served on the Board of Directors of Amira Pharmaceuticals, AnaptysBio, Inc., Cianna Medical, Inc., Elevation Pharmaceuticals, Inc., FoldRx Pharmaceuticals, Inc., InSound Medical, Inc., NeuroTherapeutics Pharma, Inc., Nora Therapeutics, Inc., Panmira Pharmaceuticals LLC, Spinifex, Inc., Synosia Therapeutics, Inc., and Verax Biomedical, Inc
Age: 49 Chairman Since 2008 Ph.D
Lukatch received his Ph.D. in Neuroscience from Stanford University where he was a DOD USAF Fellow, and his B.A. in Biochemistry from the University of California at Berkeley.
Heath Lukatch Latest Insider Activity
The company has return on total asset (ROA)
of 7.32 %
which means that it generated profit of $7.32 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE)
of 10.27 %
meaning that it created $10.27 on every $100 dollars invested by stockholders.
Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California. Inogen operates under Medical Devices classification in USA and traded on NASDAQ. It employs 770 people.Inogen (INGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 770 people. Inogen is listed under Medical Equipment category by Fama And French industry classification.
Inogen Leadership Team
|Scott Beardsley, Director|
|Byron Myers, Founder, MBA|
|Raymond Huggenberger, CEO|
|Heath Lukatch, Chairman, Ph.D|
|Heather Rider, Director, MBA|
|Loren McFarland, Director, CFA|
|Scott Greer, Director, MBA|
|Benjamin AndersonRay, Director, MBA|
|Matthew Scribner, President, MBA|
|Alison Bauerlein, Founder|
|Scott Wilkinson, COO, MBA|
|Brenton Taylor, Founder|
Stock Performance Indicators
Most of Macroaxis users are currently bullish on Inogen. What is your judgment towards investing in Inogen? Are you bullish or bearish?
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis
. Please also try Stock Tickers
module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.